Skip to main content
OpenTrials
Completed

NCT Number: NCT04066868

Evaluating the Use of Patient-Reported Outcome Measures for Improving the Inter-Rater Reliability of Common Terminology Criteria for Adverse Event Ratings

This open randomized trial investigates, if clinicians complete CTCAE ratings differently when receiving patients' patient-reported outcome (PRO) data prior to their CTCAE completion. The primary objective is to demonstrate superior inter-rater reliability of CTCAE ratings from physicians relying on EORTC PRO data as additional data source over traditional CTCAE ratings not including PRO information.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bezirkskrankenhaus Kufstein

Kufstein, 6330, Austria

About this study

In oncology, detection and tracking of adverse events (AEs) are a top priority in both clinical trials and routine care. The classification of AEs mostly relies on the Common Toxicity Terminology for Adverse Events (CTCAE) developed by the US-American National Institutes of Health and the National Cancer Institute.

It is known, however, that the assessment of AEs can greatly vary depending on whether they are assessed by patients or by clinicians.

Procedure: The patients (any oncological diagnosis, day clinic or inpatient for treatment with chemotherapy or immunotherapy; open 1:1 randomized) fill out an EORTC quality of life questionnaire electronically (C30 + further questions). These PRO data are immediately available for the clinicians. Independently of each other, two different clinicians conduct a medical consultation with the patient and electronically a CTCAE rating. For the intervention Group, clinicians see the PRO values directly next to the input options for the CTCAE rating. For the control Group, clinicians see the input options for the CTCAE rating. The similarity of the assessments is checked using intra-class correlation.

The combined use of PROs and CTCAE data makes particular sense for AEs/aspects that are directly experienced by the patient (fatigue, pain, cognitive problems, emotional functioning, ...) and can only be adequately recorded by the clinician through communication with the patient.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • any Cancer diagnosis
  • current treatment with chemotherapy or immunotherapy
  • symptom burden equal or greater score 3 of the screening question "On a scale of 0 to 10, to what degree did you experience physical or emotional symptoms/problems during the last week?"
  • ability to understand the questions linguistically and cognitively
  • written informed consent

Exclusion Criterion:

  • psychiatric diagnosis or mental health problems

Treatment and study plan

Patient-reported outcomes assessment

Other

Patient-reported outcomes are electronically assessed using EORTC QOL measures

CTCAE rating

Other

CTCAE Ratings are conducted by clinicians

PRO data is displayed

Other

PRO data is displayed right next to the CTCAE rating

Primary outcomes

  1. EORTC Quality of Life Questionnaire C30 and additional questions from the EORTC Item Library

    Time frame: single assessment of quality of life before the medical consultation

    patient-reported quality of life

  2. CTCAE V5.0

    Time frame: single assessment during the medical consultation with physician 1 on the same day of PRO assessment

    physician 1 rates patient symptoms (17 CTCAE domains matching the EORTC C30 and additional questions)

  3. CTCAE V5.0

    Time frame: single assessment during the medical consultation with physician 2 on the same day of PRO assessment

    physician 2 rates patient symptoms (17 CTCAE domains matching the EORTC C30 and additional questions)

Sponsors and collaborators

Lead sponsor

Medical University Innsbruck

Other

Collaborators

  • Bezirkskrankenhaus Kufstein
  • Centre Hospitalier Universitaire de Besancon
  • Clinical Hospital Center Rijeka
  • Kansai Medical University
  • King Hussein Cancer Center
  • Martin-Luther-Universität Halle-Wittenberg
  • N.N. Blokhin National Medical Research Center of Oncology
  • Rigshospitalet, Denmark
  • Tata Memorial Hospital
  • Università di Cagliari

Registry information

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Aug 26, 2019
Registry last updated
Apr 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.